XellSmart Bio

🗓 Founded 2021👥 2 employees💰 Last funded 2022
Research Services
LinkedIn
XellSmart is a biotechnology company dedicated to developing scalable, low-cost, allogeneic stem cell therapies derived from induced pluripotent stem cells (iPSCs) to treat major degenerative diseases with high unmet medical need—such as ALS and Parkinson’s disease. With in-house GMP manufacturing, a state-of-the-art R&D center, and FDA-recognized clinical programs, we are transforming cutting-edge science into accessible, off-the-shelf regenerative solutions. This page is dedicated to sharing our journey, achievements, and breakthroughs as we work to reshape the future of neurological care.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
China
1
Frequently asked questions
Who invested in XellSmart Bio?
XellSmart Bio has 1 investors on record on gritt.io, including 1 early-stage backers.
When did XellSmart Bio last raise funding?
The most recent investment in XellSmart Bio recorded on gritt.io was in 2022.
When was XellSmart Bio founded?
XellSmart Bio was founded in 2021.
What industry is XellSmart Bio in?
XellSmart Bio operates in Research Services. Find similar Research Services investors on gritt.io.